Positive and negative regulatory roles of the WW-like domain in TEL-PDGFβR transformation
Open Access
- 15 July 2004
- journal article
- Published by American Society of Hematology in Blood
- Vol. 104 (2), 535-542
- https://doi.org/10.1182/blood-2004-01-0169
Abstract
TEL-platelet-derived growth factor-β receptor (TEL-PDGFβR) is expressed in chronic myelomonocytic leukemias associated with t(5;12)(q33;p13), and the fusion tyrosine kinase retains a conserved WW-like domain in the PDGFβR autoinhibitory juxtamembrane region. Here we report that mutation of the 2 conserved tryptophan residues of the WW-like domain has opposing effects on TELPDGFβR kinase activation. Alanine substitution of W593, essential for protein-protein interaction in the context of other WW domains, impaired TEL-PDGFβR-mediated transformation of hematopoietic cells due to inhibition of TEL-PDGFβR kinase activity. In contrast, alanine substitution of W566, essential for structural integrity of WW domain in other contexts, had no effect on TEL-PDGFβR activation and oncogenic activity. Surprisingly, however, the W566A mutation suppressed the W593A phenotype. Double mutant W566A/W593A was indistinguishable from the wild-type fusion protein with regard to kinase activity, ability to confer factor-independent growth to Ba/F3 cells, or ability to induce a myeloproliferative disease in mice. Additional mutational analysis identified other substitutions within the WW-like domain in addition to W566A that could also suppress the W593A phenotype, including mutations predicted to diminish the autoinhibitory function of the juxtamembrane region. Therefore, the WW-like domain in the context of TELPDGFβR may have both positive and negative regulatory roles in kinase activation. (Blood. 2004;104:535-542)Keywords
This publication has 34 references indexed in Scilit:
- The TEL/PDGFβR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathwaysBlood, 2001
- H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor β gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22)Blood, 2001
- TEL/PDGFβR fusion protein activates STAT1 and STAT5Experimental Hematology, 2000
- Fatal myeloproliferation, induced in mice by TEL/PDGFβR expression, depends on PDGFβR tyrosines 579/581Journal of Clinical Investigation, 2000
- TEL/PDGFβR Induces Hematologic Malignancies in Mice That Respond to a Specific Tyrosine Kinase InhibitorBlood, 1999
- Signal transduction via platelet-derived growth factor receptorsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1998
- A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFRbeta oncoproteinThe EMBO Journal, 1997
- The TEL/platelet-derived growth factor β receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFβR kinase-dependent signaling pathwaysProceedings of the National Academy of Sciences, 1996
- Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocationCell, 1994
- Phospholipase C-γ1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signalCell, 1993